Maurizio Rainisio

Dr. Maurizio Rainisio

orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in The Lancet
Verified
Journal Article
Closed access
RCRichard N Channick
Richard N Channick
GSGérald Simonneau
Gérald Simonneau
OSOlivier Sitbon
Olivier Sitbon
IRIvan M Robbins
Ivan M Robbins
AFAdaani Frost
Adaani Frost
LRLewis J Rubin
Lewis J Rubin

1 August 2002 in JACC
Verified
Journal Article
Closed access
OSOlivier Sitbon
Olivier Sitbon
MHMarc Humbert
Marc Humbert
HNHilario Nunes
Hilario Nunes
FPFlorence Parent
Florence Parent
GGGilles Garcia
Gilles Garcia
GSG.éRald Simonneau
G.éRald Simonneau

8 December 2004 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
JKJ H Korn
J H Korn
MMM Mayes
M Mayes
MCM Matucci Cerinic
M Matucci Cerinic
MRMaurizio Rainisio
Maurizio Rainisio
JPJ Pope
J Pope
CBCarol Black
Carol Black
Objective: Recurrent digital ulcers are a manifestation of vascular disease in patients with systemic sclerosis (SSc; scleroderma) and lead to pain, impaired function, and tissue loss. We investigated whether treatment with the endothelin receptor antagonist, bosentan, decreased the development of new digital ulcers in patients with SSc.Methods: This was a randomized, prospective, placebo‐controlled, double‐blind study of 122 patients at 17 centers in Europe and North America, evaluating the effect of treatment on prevention of digital ulcers. The primary outcome variable was the number of new digital ulcers developing during the 16‐week study period. Secondary assessments included healing of existing digital ulcers and evaluation of hand function using the Scleroderma Health Assessment Questionnaire.Results: Patients receiving bosentan had a 48% reduction in the mean number of new ulcers during the treatment period (1.4 versus 2.7 new ulcers; P = 0.0083). Patients who had digital ulcers at the time of entry in the study were at higher risk for the development of new ulcers; in this subgroup the mean number of new ulcers was reduced from 3.6 to 1.8 (P = 0.0075). In patients receiving bosentan, a statistically significant improvement in hand function was observed. There was no difference between treatment groups in the healing of existing ulcers. Serum transaminase levels were elevated to >3‐fold the upper limit of normal in bosentan‐treated patients; this elevation is comparable with that observed in previous studies of this agent. Other side effects were similar in the 2 treatment groups.Conclusion: Endothelins may play an important role in the pathogenesis of vascular disease in patients with SSc. Treatment with the endothelin receptor antagonist bosentan may be effective in preventing new digital ulcers and improving hand function in patients with SSc.

1 February 2005 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
VMV. V. McLaughlin
V. V. McLaughlin
OSO. Sitbon
O. Sitbon
DBD. B. Badesch
D. B. Badesch
RBR. J. Barst
R. J. Barst
CBC. Black
C. Black
LRL. J. Rubin
L. J. Rubin
Primary pulmonary hypertension (PPH) is a progressive disease with high mortality. Administration ofi.v.epoprostenol has demonstrated improved exercise tolerance, haemodynamics, and survival. The orally active, dual endothelin receptor antagonist bosentan improves exercise endurance, haemodynamics, and functional class over the short term. To determine the effect of first-line bosentan therapy on survival, this study followed 169 patients with PPH treated with bosentan in two placebo-controlled trials and their extensions.Data on survival and alternative treatments were collected from September 1999 (start of the first placebo-controlled study) to December 31, 2002. Observed survival up to 36 months was reported as Kaplan-Meier estimates and compared with predicted survival as determined for each patient by the National Institutes of Health Registry formula.Kaplan-Meier survival estimates were 96% at 12 months and 89% at 24 months. In contrast, predicted survival was 69% and 57%, respectively. In addition, at the end of 12 and 24 months, 85% and 70% of patients, respectively, remained alive and on bosentan monotherapy. Factors that predicted a worse outcome included World Health Organization Functional Class IV and 6-min walk distance below the median (358 m) at baseline.First-line bosentan therapy was found to improve survival in patients with advanced primary pulmonary hypertension.

7 November 2007 in JAMA
Verified
Journal Article
Open access
PDF file
JMJohn J. V. McMurray
John J. V. McMurray
JTJohn R. Teerlink
John R. Teerlink
GCGad Cotter
Gad Cotter
RBRobert C. Bourge
Robert C. Bourge
JCJohn George Franklin Cleland
John George Franklin Cleland
FIfor the VERITAS Investigators
for the VERITAS Investigators
Acute heart failure is a common cause of emergency admission to hospital.1-3 The principal symptom, dyspnea, is thought to be caused by an increase in pulmonary capillary wedge pressure (PCWP), often associated with a decrease in stroke volume and cardiac index and increase in systemic vascular resistance.1-3 The immediate aims of treatment are to relieve dyspnea and to improve and stabilize the patient's hemodynamic and clinical state.1-5 Additional goals are prevention of death and readmission, both of which occur frequently.1-5

1 April 2003 in JACC
Verified
Journal Article
Closed access
NGNazzareno Galiè
Nazzareno Galiè
AHAlan L. Hinderliter
Alan L. Hinderliter
Adam TorbickiAdam Torbicki
Adam Torbicki
TFThierry Fourme
Thierry Fourme
GSGerald Simonneau
Gerald Simonneau
LRLewis Rubin
Lewis Rubin